Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
October 14, 2022 4:05 PM EDTWorkforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Companys cash runway into Q2 CY2024The Company plans to maximize shareholder value by focusing R&D resources on advancement of the differentiated gene editing capabilities of the Companys platform Company to reduce activities and pursue partnerships for myotonic dystrophy type 1 (DM1), Huntingtons disease (HD), and KRAS (G12D & G12V) programsDov A. Goldstein,... More
